Welcome to our dedicated page for LeonaBio SEC filings (Ticker: LONA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LeonaBio, Inc. SEC filings document the company’s status as a Delaware clinical-stage biopharmaceutical issuer listed on The Nasdaq Capital Market under the LONA ticker. Its 8-K reports furnish financial results, business updates, Regulation FD disclosures, board matters, and material events tied to its product candidates and corporate development activity.
Registration statement amendments cover delayed or continuous securities offerings, while amended material-event filings document the completed Sermonix license transaction, related securities issuance, and SEC accounting disclosures under Regulation S-X. The filing record also reflects the company’s transition from Athira Pharma to LeonaBio and the capital-structure disclosures associated with its common stock and warrants.
LeonaBio, Inc. executive Mark Worthington reported a mix of share transactions tied to vesting equity awards. On March 3, 2026, 5,726 restricted stock units were exercised into the same number of common shares at $0.00 per share, reflecting a standard RSU conversion.
On March 4, 2026, 1,328 common shares were sold in an open-market transaction at a weighted-average price of $5.37 per share to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policies, which the filing notes was not a discretionary sale. After these transactions, Worthington directly held 18,376 common shares.
LeonaBio, Inc. executive Mark Worthington reported a mix of share transactions tied to vesting equity awards. On March 3, 2026, 5,726 restricted stock units were exercised into the same number of common shares at $0.00 per share, reflecting a standard RSU conversion.
On March 4, 2026, 1,328 common shares were sold in an open-market transaction at a weighted-average price of $5.37 per share to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policies, which the filing notes was not a discretionary sale. After these transactions, Worthington directly held 18,376 common shares.
LeonaBio, Inc. Chief Scientific Officer Kevin Church reported RSU vesting and related share transactions. On March 3, he exercised 5,856 restricted stock units, each converting into one share of common stock at a stated price of $0.00 per share.
Those RSUs, originally granted as 5,856 units on March 3, 2025 and vesting in full one year later, increased his common stock holdings. On March 4, 1,359 common shares were sold in open-market transactions at a weighted-average price of $5.37 per share solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policy.
After these transactions, Church directly held 25,178 shares of LeonaBio common stock.
LeonaBio, Inc. Chief Scientific Officer Kevin Church reported RSU vesting and related share transactions. On March 3, he exercised 5,856 restricted stock units, each converting into one share of common stock at a stated price of $0.00 per share.
Those RSUs, originally granted as 5,856 units on March 3, 2025 and vesting in full one year later, increased his common stock holdings. On March 4, 1,359 common shares were sold in open-market transactions at a weighted-average price of $5.37 per share solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policy.
After these transactions, Church directly held 25,178 shares of LeonaBio common stock.
LeonaBio, Inc.’s chief medical officer Javier San Martin reported equity compensation activity and a related tax sale. On March 3, 2026, 7,418 restricted stock units (RSUs) fully vested and were converted into 7,418 shares of common stock at a stated price of $0.00 per share.
On March 4, 2026, 1,720 shares of common stock were sold in open-market transactions at a weighted-average price of $5.37 per share, solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policies, and not as a discretionary sale. After these transactions, Javier San Martin directly owned 15,887 shares of LeonaBio common stock.
LeonaBio, Inc.’s chief medical officer Javier San Martin reported equity compensation activity and a related tax sale. On March 3, 2026, 7,418 restricted stock units (RSUs) fully vested and were converted into 7,418 shares of common stock at a stated price of $0.00 per share.
On March 4, 2026, 1,720 shares of common stock were sold in open-market transactions at a weighted-average price of $5.37 per share, solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policies, and not as a discretionary sale. After these transactions, Javier San Martin directly owned 15,887 shares of LeonaBio common stock.
LeonaBio, Inc. (ATHA) filed a Rule 144 notice to sell 22,254 shares of common stock tied to an equity compensation event.
The filing also reports 2,586 shares sold in the past three months and lists a 03/04/2026 transaction date for the restricted stock lapse.
LeonaBio, Inc. (ATHA) filed a Rule 144 notice to sell 22,254 shares of common stock tied to an equity compensation event.
The filing also reports 2,586 shares sold in the past three months and lists a 03/04/2026 transaction date for the restricted stock lapse.
LeonaBio, Inc. is asking stockholders to approve several capital and governance proposals at a virtual special meeting on March 18, 2026. The company seeks approval to issue 5,502,402 shares of common stock upon exercise of a pre-funded warrant held by Sermonix, and to allow Sermonix and Perceptive to exercise their warrants even if their ownership exceeds 19.99%, as required by Nasdaq Rule 5635(b). Stockholders are also asked to approve a new 2026 Equity Incentive Plan with an initial reserve of 5,700,000 shares plus an evergreen increase, amend the charter to increase authorized common stock, and permit adjournment if more time is needed to secure votes. If key proposals fail, LeonaBio may owe Sermonix up to $7.5 million in redemptions and would have fewer shares available for future financings and incentives.
LeonaBio, Inc. is asking stockholders to approve several capital and governance proposals at a virtual special meeting on March 18, 2026. The company seeks approval to issue 5,502,402 shares of common stock upon exercise of a pre-funded warrant held by Sermonix, and to allow Sermonix and Perceptive to exercise their warrants even if their ownership exceeds 19.99%, as required by Nasdaq Rule 5635(b). Stockholders are also asked to approve a new 2026 Equity Incentive Plan with an initial reserve of 5,700,000 shares plus an evergreen increase, amend the charter to increase authorized common stock, and permit adjournment if more time is needed to secure votes. If key proposals fail, LeonaBio may owe Sermonix up to $7.5 million in redemptions and would have fewer shares available for future financings and incentives.
LeonaBio, Inc. has filed a resale registration statement covering up to 5,502,402 shares of common stock that may be sold from time to time by Sermonix Pharmaceuticals and its permitted transferees. These shares are issuable upon exercise of a pre-funded warrant that Sermonix received in connection with a December 2025 license agreement granting LeonaBio exclusive rights to develop and commercialize lasofoxifene in certain territories.
LeonaBio will not receive any proceeds from Sermonix’s resale of the registered shares, but would receive up to approximately $5,502 in gross proceeds if the warrant is fully exercised for cash at an exercise price of $0.001 per share, which it plans to use for working capital and to advance lasofoxifene and other pipeline drug candidates. As of December 31, 2025, 9,335,913 shares of common stock were outstanding, separate from the shares covered by this resale registration.
LeonaBio, Inc. has filed a resale registration statement covering up to 5,502,402 shares of common stock that may be sold from time to time by Sermonix Pharmaceuticals and its permitted transferees. These shares are issuable upon exercise of a pre-funded warrant that Sermonix received in connection with a December 2025 license agreement granting LeonaBio exclusive rights to develop and commercialize lasofoxifene in certain territories.
LeonaBio will not receive any proceeds from Sermonix’s resale of the registered shares, but would receive up to approximately $5,502 in gross proceeds if the warrant is fully exercised for cash at an exercise price of $0.001 per share, which it plans to use for working capital and to advance lasofoxifene and other pipeline drug candidates. As of December 31, 2025, 9,335,913 shares of common stock were outstanding, separate from the shares covered by this resale registration.
LeonaBio, Inc. has filed a resale registration covering up to 58,464,567 shares of common stock for potential sale by existing selling stockholders. These shares include stock already issued and shares issuable upon exercise of pre-funded warrants and common warrants that were originally sold in a December 2025 private placement. LeonaBio will not receive proceeds from any resale of shares by these holders, but could receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share and approximately $146,249,987 from cash exercise of 23,031,494 common warrants at $6.35 per share. The company plans to use any such warrant exercise proceeds for working capital and to advance its drug pipeline, including lead candidates lasofoxifene and ATH-1105. Its common stock trades on Nasdaq under the symbol “LONA.”
LeonaBio, Inc. has filed a resale registration covering up to 58,464,567 shares of common stock for potential sale by existing selling stockholders. These shares include stock already issued and shares issuable upon exercise of pre-funded warrants and common warrants that were originally sold in a December 2025 private placement. LeonaBio will not receive proceeds from any resale of shares by these holders, but could receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share and approximately $146,249,987 from cash exercise of 23,031,494 common warrants at $6.35 per share. The company plans to use any such warrant exercise proceeds for working capital and to advance its drug pipeline, including lead candidates lasofoxifene and ATH-1105. Its common stock trades on Nasdaq under the symbol “LONA.”